Contact: Cheryl Gardner
Phone: (650) 770-0201 X 1012
FOR IMMEDIATE RELEASE
PARKINSON’S INSTITUTE AND CLINICAL CENTER AT THE FOREFRONT OF ESSENTIAL TREMOR RESEARCH WITH LARGEST THERAPEUTIC TRIAL
– Data Show Wrist-Worn Neuromodulation Therapy Significantly Reduces Hand Tremor –
MOUNTAIN VIEW, CA (October 2, 2019) – Researchers from the Parkinson’s Institute and Clinical Center (PICC) participated in the largest therapeutic trial ever conducted in essential tremor (ET) called PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT). The landmark study found that nerve stimulation with Cala Therapy can significantly reduce hand tremors as measured by validated physician and patient assessment scales and motion sensor data. Topline results from PROSPECT were presented recently in a late-breaking poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Nice, France.
Cala Therapy, now marketed as Cala TrioTM, is a wrist-worn neuromodulation therapy that provides symptomatic relief of ET in the hand. ET is the most prevalent tremor disorder and one of the most common neurological disorders affecting approximately 7 million people in the United States. It can affect almost any part of the body, but the trembling most often occurs in the hands, making everyday activities such as eating, writing, or getting dressed extremely difficult. Current ET treatments include mostly off-label use of medications or brain surgery.
“We are proud to be at the forefront of ET research and part of the largest therapeutic trial in this chronic and progressive disease,” said Dr. Christopher Way, D.O., lead investigator of PROSPECT at PICC. “Non-invasive treatment with Cala Trio represents a novel approach to managing hand tremor and more importantly, it provides patients with a safe and effective therapeutic option.” The Parkinson’s Institute and Clinical Center is one of the select locations in the country to make Cala Trio available to patients by prescription. Visit www.parkinsonsinstitute.org to learn more.
About the Parkinson’s Institute and Clinical Center
Parkinson’s Institute and Clinical Center (PICC) is a 501(c)(3) nonprofit organization providing Parkinson’s and other movement disorders patients with personalized, compassionate care, and access to cutting-edge clinical trials. PICC is a leader in innovative research to transform the field of Parkinson’s treatment and the fight to find a cure. For more information, visit www.parkinsonsinstitute.org.
About Essential Tremor (ET)
ET is the most prevalent tremor disorder and one of the most common neurological disorders, affecting an estimated 7 million people in the United States. It is a chronic condition that causes involuntary and rhythmic shaking and typically worsens over time. ET can affect almost any part of the body, but the trembling most often occurs in the hands, making everyday activities such as eating, writing, or getting dressed extremely difficult. ET is often confused with Parkinson’s disease, although it is eight times more common. A key difference is that hand tremors caused by essential tremor happen with goal-directed movement (with intention) whereas Parkinson’s disease tremors occur mostly at rest. Current ET treatments include mostly off-label use of medications or brain surgery.
About Cala TrioTM
Cala Trio is a breakthrough on-demand therapy for hand tremor in adults with essential tremor (ET). The wrist-worn neuromodulation device is the only non-invasive individualized therapy for ET. Cala Trio is calibrated to each patient’s hand tremor. When activated, the device gently stimulates the nerves responsible for the tremor to provide symptomatic relief. Cala Trio is FDA cleared and currently available by prescription in select US markets. To learn more, visit www.CalaTrio.com.
About Cala Health
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. Cala Health’s lead product, Cala TrioTM, is the only non-invasive prescription therapy for essential tremor and is now available through a unique digital business model of direct-to-patient solutions. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. For more information, visit www.CalaHealth.com.